12:00 AM
Feb 19, 2007
 |  BioCentury  |  Emerging Company Profile

GeNeuro: Unraveling secrets of HERV

GeNeuro S.A. thinks its work on human endogenous retroviruses may have uncovered the cause of neurodegenerative diseases like multiple sclerosis and as a result may offer a new therapeutic strategy. The company has an antibody against a HERV-W envelope protein in preclinical testing.

"Originally it was suspected that an HTLV - or human T-lymphotropic virus - was causing MS," CSO Herve Perron told BioCentury. "So when I found in 1989 a retrovirus in MS patients, it was not totally unexpected." The 1989 finding was published in Research in Virologyand confirmed in a 1991 Lancet publication, also by Perron.

What was unexpected was the type of retrovirus he had discovered. "It belonged to a totally unstudied category of retroviruses," Perron said.

Much of Perron's work was done while he was at bioMérieux S.A. (Euronext:BIM, Marcy l'Etoile, France), which has since chosen to focus exclusively on diagnostics. Perron, BIM and Eclosion S.A., a Geneva...

Read the full 742 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >